KAICO

Nishiku, Japan

KAICO is a biotechnology company that provides hard-expressing proteins to develop drugs with a silkworm-baculovirus expression system.

$3.8M raised

Apr 2025

Series B

Top Investors

Mizuho CapitalFFG Venture Business PartnersITOCHU Technology VenturesJMTC CapitalHigin Capital

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has KAICO raised?

KAICO has raised $3.8M in total funding. The most recent round was Series B. The last funding was announced in April 2025.

Who are KAICO's investors?

KAICO's investors include Mizuho Capital, FFG Venture Business Partners, ITOCHU Technology Ventures, JMTC Capital, Higin Capital.

Where is KAICO headquartered?

KAICO is headquartered in Nishiku, Japan.

What does KAICO do?

KAICO is a biotechnology company that provides hard-expressing proteins to develop drugs with a silkworm-baculovirus expression system.

What stage is KAICO at?

KAICO is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 15, 2025.

MLA

"KAICO — Funding & Investors." VCBacked, April 15, 2025, https://www.vcbacked.co/company/kaico. Accessed June 3, 2026.

APA

VCBacked. (2025). KAICO — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/kaico

Wikipedia (cite web)

{{cite web |title=KAICO — Funding & Investors |url=https://www.vcbacked.co/company/kaico |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 15, 2025.